RVAC Medicines
Singapore
About RVAC Medicines
RVAC Medicines is an mRNA platform company with a pipeline of novel products covering a wide range of disease areas. The company is building a pipeline of novel mRNA vaccines and therapeutics to address unmet medical needs, particularly in emerging markets. It's cutting-edge GMP manufacturing facilities that will advance its platform technologies through in-house research and development and external partnerships, enabling the production of cutting-edge mRNA and nucleic acid delivery technologies. RVAC Medicines was founded in 2021 and is based in Singapore.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $140.0M
- Funding stage: Early Stage Venture
- Last round: Series B (Apr 2022)
- Website: rvacmed.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Product Research
Social Profiles
Canonical: https://fsome.com/organization/rvac-medicines-9082 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.